Stocktoria
Benitec Biopharma Inc. BNTC
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2012-07-11
Benitec Biopharma Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $75,000 | $73,000 | $59,000 | $102,000 | $12.2M |
| R&D expense | $18.3M | $15.6M | $12.8M | $11.3M | $7.0M | $3.0M | $4.6M |
| Operating income | -$41.8M | -$22.5M | -$19.1M | -$17.9M | -$13.6M | -$8.3M | $2.6M |
| Net income | -$37.9M | -$21.8M | -$19.6M | -$18.2M | -$13.9M | -$8.3M | $2.6M |
| EPS (diluted) | $-1.05 | $-1.22 | $-14.12 | $-37.88 | $-3.23 | — | — |
| Operating cash flow | -$23.6M | -$19.4M | -$18.0M | -$15.9M | -$12.8M | -$7.5M | $4.8M |
| Free cash flow | -$23.6M | -$19.6M | -$18.0M | -$15.9M | -$13.1M | -$7.6M | $4.4M |
| Cash & equivalents | $97.7M | $50.9M | $2.5M | $4.1M | $19.8M | $9.8M | $15.7M |
| Total assets | $99.6M | $52.2M | $4.5M | $6.0M | $21.4M | $11.6M | $19.2M |
| Total liabilities | $2.3M | $5.0M | $4.3M | $3.1M | $1.4M | $1.3M | $2.6M |
| Shareholders' equity | $97.3M | $47.2M | $202,000 | $2.9M | $20.0M | $10.2M | $16.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | +2.7% | +23.7% | -42.2% | -99.2% | — |
| Net income growth | — | — | — | — | — | -417.1% | — |
| Free cash flow growth | — | — | — | — | — | -274.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.